Showing results (1-10 of 52) with videos related to
Sort By:
Pageof 6
Seminars in Oncology|October 23, 2003
The development of differentiation agents for the treatment of prostate cancerMatt Galsky, W Kevin KellyJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2005
High-risk localized prostate cancer: a case for early chemotherapyMartin Gleave, W Kevin KellyNature Clinical Practice. Oncology|December 3, 2008
Epothilones: tubulin polymerization as a novel target for prostate cancer therapyJames J Lee, W Kevin KellyTherapeutic Advances in Medical Oncology|June 15, 2010
Redefining hormone resistance in prostate cancerChristopher J Hoimes, W Kevin KellyThe Canadian Journal of Urology|December 10, 2022
Neuroendocrine transformation of prostate adenocarcinoma with corpora cavernosa metastasesHalle Foss, Radhika Ragam, W Kevin Kelly, et al.Urology Case Reports|February 25, 2026
Metastatic castrate-resistant prostate cancer to the penis resulting in malignant priapism and urethral obstructionCourtney Stewart, Joon Yau Leong, W Kevin Kelly, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2009
An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancerGlenn Liu, W Kevin Kelly, George Wilding, et al.Nutrients|January 8, 2025
Evaluating the Impact of a Novel Program to Address Acute Food Insecurity Among Cancer PatientsElliott M Sina, Michael Rowe, Gina Mancuso, et al.Clinical Lung Cancer|March 4, 2006
Potential role of histone deacetylase inhibitors in mesothelioma: clinical experience with suberoylanilide hydroxamic acidLee M Krug, Tracy Curley, Lawrence Schwartz, et al.Urology|February 1, 2003
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trialDavid Andrew Verbel, W Kevin Kelly, Oren Smaletz, et al.Pageof 6